efficacy

Related by string. Efficacy * * Demonstrates Efficacy . primary efficacy endpoint . secondary efficacy endpoints . therapeutic efficacy . efficacy endpoints . vivo efficacy . primary efficacy endpoints . efficacy endpoint . efficacy tolerability . analgesic efficacy . luminous efficacy . antimicrobial efficacy . antiviral efficacy . preclinical efficacy . secondary efficacy endpoint *

Related by context. Frequent words. (Click for all words.) 74 tolerability 69 tolerability profile 67 effectiveness 66 Efficacy 66 immunogenicity 66 pharmacokinetic profile 66 antiviral activity 64 pharmacokinetic 64 antitumor activity 64 pharmacokinetics 62 efficacy endpoints 62 clinical trial 62 bioavailability 62 clinical trials 61 dosing regimens 61 pharmacodynamic 60 pharmacodynamics 60 bioequivalence 60 efficacious 60 Phase 2b study 60 clinical endpoints 59 preclinical studies 59 randomized clinical trials 59 monotherapy 59 non inferiority 59 placebo controlled 59 randomized trials 58 safety tolerability 58 Phase IIa trial 58 Phase 2a clinical 57 tiotropium 57 CRx 57 MGCD# [002] 57 adalimumab 57 pharmacologic 57 CYT# 57 mg dose 57 Phase IIa clinical 57 randomized controlled 57 randomized clinical 57 Phase Ib 56 Zenvia 56 Phase IIb 56 Preclinical studies 56 FTY# 56 HspE7 56 Phase IIa 56 Alpharadin 56 telbivudine 56 antiplatelet 56 cethromycin 56 Phase IIb clinical 55 randomized placebo controlled 55 toxicity 55 dosing 55 randomized controlled trials 55 IMGN# 55 Phase III trials 55 investigational compound 55 Phase 1b 55 vitro studies 55 Phase III clinical 55 investigational 54 clinically meaningful 54 lubiprostone 54 clinically relevant 54 adjunctive 54 ISIS # 54 investigational drug 54 picoplatin 54 cytotoxicity 54 Phase 2b trial 54 ZYBRESTAT 54 Phase 2b clinical 54 primary endpoint 54 mg doses 54 rivaroxaban 54 JANUVIA 54 dose escalation 54 fluconazole 53 docetaxel 53 celecoxib 53 LEVADEX 53 potency 53 PF # [001] 53 Phase 2a 53 preclinical 53 plus ribavirin 53 budesonide 53 neurotoxicity 53 bavituximab 53 PEG INTRON 53 prospective randomized 53 double blind placebo 53 INCB# [002] 53 orally administered 53 therapeutic efficacy 53 randomized controlled trial 53 clinical 53 FOLFOX 53 Phase III clinical trials

Back to home page